SummitTX Capital L.P. Grows Stock Position in Establishment Labs Holdings Inc. $ESTA

SummitTX Capital L.P. increased its stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 30.0% in the first quarter, HoldingsChannel reports. The fund owned 44,923 shares of the company’s stock after purchasing an additional 10,356 shares during the period. SummitTX Capital L.P.’s holdings in Establishment Labs were worth $2,551,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Nantahala Capital Management LLC increased its stake in Establishment Labs by 11.1% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,973,492 shares of the company’s stock worth $80,893,000 after purchasing an additional 197,962 shares during the period. Bamco Inc. NY boosted its stake in shares of Establishment Labs by 21.5% during the second quarter. Bamco Inc. NY now owns 907,537 shares of the company’s stock valued at $38,761,000 after purchasing an additional 160,755 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Establishment Labs by 117.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock valued at $59,145,000 after purchasing an additional 438,206 shares during the period. Mudita Advisors LLP boosted its stake in shares of Establishment Labs by 1.9% during the fourth quarter. Mudita Advisors LLP now owns 699,703 shares of the company’s stock valued at $50,994,000 after purchasing an additional 12,939 shares during the period. Finally, Balyasny Asset Management L.P. grew its holdings in shares of Establishment Labs by 50.9% in the second quarter. Balyasny Asset Management L.P. now owns 488,688 shares of the company’s stock worth $20,872,000 after purchasing an additional 164,788 shares during the last quarter. 72.91% of the stock is currently owned by institutional investors.

Establishment Labs Trading Down 0.2%

NASDAQ ESTA opened at $91.90 on Wednesday. The stock has a market cap of $2.70 billion, a P/E ratio of -61.68 and a beta of 1.06. Establishment Labs Holdings Inc. has a fifty-two week low of $33.35 and a fifty-two week high of $96.99. The stock has a 50 day simple moving average of $83.63 and a two-hundred day simple moving average of $73.08. The company has a debt-to-equity ratio of 16.82, a quick ratio of 1.91 and a current ratio of 2.96.

Establishment Labs (NASDAQ:ESTA) last posted its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.10). Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. The business had revenue of $59.88 million for the quarter, compared to analysts’ expectations of $57.40 million. During the same period last year, the firm posted ($0.70) earnings per share. Establishment Labs’s quarterly revenue was up 44.7% on a year-over-year basis. On average, analysts forecast that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Quiros Juan Jose Chacon sold 105,000 shares of Establishment Labs stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total value of $7,919,100.00. Following the sale, the director owned 927,504 shares in the company, valued at $69,952,351.68. The trade was a 10.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 180,000 shares of company stock valued at $13,225,275 over the last ninety days. Company insiders own 9.99% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on ESTA. BTIG Research reaffirmed a “buy” rating on shares of Establishment Labs in a research note on Monday, July 13th. Mizuho increased their price target on shares of Establishment Labs from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. TD Cowen reissued a “buy” rating on shares of Establishment Labs in a report on Monday, June 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a research report on Wednesday, June 24th. Finally, Citigroup boosted their price objective on shares of Establishment Labs from $76.00 to $92.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $90.43.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.